News from Novo Nordisk A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Novo Nordisk

26 Aug, 2018, 13:00 BST Ozempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal...


23 Jun, 2018, 15:12 BST Tresiba® Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycaemia Versus Insulin Glargine U300 in Real-World Evidence Study

Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of...


23 Jun, 2018, 15:09 BST Ozempic® Provided Greater Weight Reductions for Adults With a Baseline BMI ≥25kg/m2 Than Those With Lower Baseline BMI <25kg/m2, in a SUSTAIN 7 Post-hoc Analysis

Poster Presentation #1083-P Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg,...


23 Jun, 2018, 15:06 BST Oral Semaglutide Demonstrated Significant Reduction in Blood Sugar vs Placebo in PIONEER 1 Trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in...


23 Jun, 2018, 13:05 BST Significant Blood Sugar Improvement With Xultophy® Compared to Insulin Glargine U-100 When Used as Add-On to Oral Diabetes Medications

Oral Presentation #127-OR Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no...


24 May, 2018, 07:00 BST Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda®

People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting,...


21 May, 2018, 10:45 BST Head-to-Head Trial Shows Refixia® Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia® (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those...


21 May, 2018, 09:00 BST NovoEight® Maintains Potency When Stored at 40ºC Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight® (turoctocog alfa) remains potent after three months exposure...


19 Mar, 2018, 12:00 GMT Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Oral session #12 Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of...


01 Feb, 2018, 08:30 GMT Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; Results Published in The Lancet Diabetes & Endocrinology

Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg...


11 Dec, 2017, 08:00 GMT Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

- Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has...


07 Dec, 2017, 08:45 GMT Tresiba® Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on...


07 Dec, 2017, 08:45 GMT Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar...


06 Dec, 2017, 08:01 GMT Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents...


05 Dec, 2017, 09:00 GMT Switching to Tresiba® Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting

- Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels - In people with...


05 Dec, 2017, 06:00 GMT Xultophy® Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin...


06 Nov, 2017, 08:45 GMT Switching to Tresiba® is Highly Cost-effective and Cost-saving in a Real-world Setting

Poster Presentation PDB27 A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and...


31 Oct, 2017, 12:00 GMT New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care

Despite increasing recognition of obesity as a disease, many barriers to effective care remain Few of the more than 90 million Americans with...


29 Sep, 2017, 07:00 BST IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of...


15 Sep, 2017, 08:31 BST Tresiba® Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death

Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2...


13 Sep, 2017, 15:31 BST Xultophy® Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

Oral Presentation 113 In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors...


12 Sep, 2017, 11:59 BST More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Comparator Treatments

Poster # 820 A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a...


12 Sep, 2017, 11:59 BST Fiasp® Significantly Improved Overall Blood Sugar Control in Type 1 Diabetes Long-term

Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar...


28 Aug, 2017, 13:00 BST Victoza® Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular...


03 Jul, 2017, 08:00 BST Novo Nordisk to Present 35 Abstracts at the International Society on Thrombosis and Haemostasis Congress

Novo Nordisk announced today that data from 35 abstracts will be presented at the upcoming International Society on Thrombosis and Haemostasis...